Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL)

on the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia)

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of the present study is to estimate the current incidence of febrile events (FEs) and infectious episodes in acute lymphoblastic leukemia (ALL) and evaluate the outcome. We analyzed data on all FEs in a cohort of patients affected by ALL admitted to 20 Italian hematologic centers during 21 months of observation from April 1, 2012 to December 31, 2013. Data about treatment phase, steroids, neutropenia, type and site of infection, and outcome of infection were collected. The population comprehended 271 ALL adult patients. Median age was 46 years old (range 19–75), M/F 1.1:1. We collected 179 FEs occurring during 395 different phases of treatment in 127 patients (45.3% incidence): remission induction treatment 53.1%, consolidation/maintenance 35.7%, treatment for a first or second relapse 44.3%, and refractory disease 85.7%. The incidence of FUO (fever of unknown origin) was 55/395 (13.9%). In the remaining cases, bacteria caused 92 FEs (23.2%), fungi 17 (4.3%), viruses 5 (1%). Mixed infections occurred in 10 cases mainly fungal+bacterial (9/10 cases). Neutropenia was mostly present at onset of FE (89.9% of FEs). Mortality rate was 11.7% (21/179) while 16 deaths occurred with evidence of infection (8.9%). Age > 60 years, neutropenia, poor performance status, steroids, refractory disease, and mixed infections significantly correlated with infection-related mortality. A statistically significant association with mortality was observed also for pulmonary localization and bacteremia. Our study describes the real-life epidemiological scenario of infections in ALL and identifies a subset of patients who are at higher risk for infection-related mortality.

Original languageEnglish
Pages (from-to)791-798
Number of pages8
JournalAnnals of Hematology
Volume97
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Fever
Infection
Neutropenia
Mortality
Coinfection
Incidence
Steroids
Fever of Unknown Origin
Remission Induction
Therapeutics
Bacteremia
Fungi
Maintenance
Observation
Viruses
Bacteria
Recurrence
Lung
Population

Keywords

  • Acute lymphoblastic leukemia
  • Epidemiology
  • Febrile events
  • Infections

ASJC Scopus subject areas

  • Hematology

Cite this

on the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia) (2018). Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). Annals of Hematology, 97(5), 791-798. https://doi.org/10.1007/s00277-018-3252-6

Febrile events in acute lymphoblastic leukemia : a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). / on the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia).

In: Annals of Hematology, Vol. 97, No. 5, 2018, p. 791-798.

Research output: Contribution to journalArticle

on the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia) 2018, 'Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL)', Annals of Hematology, vol. 97, no. 5, pp. 791-798. https://doi.org/10.1007/s00277-018-3252-6
on the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia). / Febrile events in acute lymphoblastic leukemia : a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). In: Annals of Hematology. 2018 ; Vol. 97, No. 5. pp. 791-798.
@article{351fe3f7a01b4b7588d452a7ba60d8e9,
title = "Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL)",
abstract = "The purpose of the present study is to estimate the current incidence of febrile events (FEs) and infectious episodes in acute lymphoblastic leukemia (ALL) and evaluate the outcome. We analyzed data on all FEs in a cohort of patients affected by ALL admitted to 20 Italian hematologic centers during 21 months of observation from April 1, 2012 to December 31, 2013. Data about treatment phase, steroids, neutropenia, type and site of infection, and outcome of infection were collected. The population comprehended 271 ALL adult patients. Median age was 46 years old (range 19–75), M/F 1.1:1. We collected 179 FEs occurring during 395 different phases of treatment in 127 patients (45.3{\%} incidence): remission induction treatment 53.1{\%}, consolidation/maintenance 35.7{\%}, treatment for a first or second relapse 44.3{\%}, and refractory disease 85.7{\%}. The incidence of FUO (fever of unknown origin) was 55/395 (13.9{\%}). In the remaining cases, bacteria caused 92 FEs (23.2{\%}), fungi 17 (4.3{\%}), viruses 5 (1{\%}). Mixed infections occurred in 10 cases mainly fungal+bacterial (9/10 cases). Neutropenia was mostly present at onset of FE (89.9{\%} of FEs). Mortality rate was 11.7{\%} (21/179) while 16 deaths occurred with evidence of infection (8.9{\%}). Age > 60 years, neutropenia, poor performance status, steroids, refractory disease, and mixed infections significantly correlated with infection-related mortality. A statistically significant association with mortality was observed also for pulmonary localization and bacteremia. Our study describes the real-life epidemiological scenario of infections in ALL and identifies a subset of patients who are at higher risk for infection-related mortality.",
keywords = "Acute lymphoblastic leukemia, Epidemiology, Febrile events, Infections",
author = "{on the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia)} and {Di Blasi}, Roberta and Chiara Cattaneo and Lewis, {Russell E.} and Mario Tumbarello and Laura Angelici and Giulia Dragonetti and Alessandro Busca and Benedetta Camb{\`o} and Anna Candoni and Monica Cesarini and Simone Cesaro and Mario Delia and Rosa Fanci and Francesca Farina and Mariagrazia Garzia and Antonio Giordano and Bruno Martino and Lorella Melillo and Gianpaolo Nadali and Vincenzo Perriello and Marco Picardi and Quinto, {Angela Maria} and Prassede Salutari and Angelica Spolzino and Adriana Vacca and Calogero Vetro and Michelle Zancanella and Annamaria Nosari and Franco Aversa and Livio Pagano",
year = "2018",
doi = "10.1007/s00277-018-3252-6",
language = "English",
volume = "97",
pages = "791--798",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Febrile events in acute lymphoblastic leukemia

T2 - a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL)

AU - on the behalf of the SEIFEM group (Sorveglianza Epidemiologica Infezioni Fungine in Ematologia)

AU - Di Blasi, Roberta

AU - Cattaneo, Chiara

AU - Lewis, Russell E.

AU - Tumbarello, Mario

AU - Angelici, Laura

AU - Dragonetti, Giulia

AU - Busca, Alessandro

AU - Cambò, Benedetta

AU - Candoni, Anna

AU - Cesarini, Monica

AU - Cesaro, Simone

AU - Delia, Mario

AU - Fanci, Rosa

AU - Farina, Francesca

AU - Garzia, Mariagrazia

AU - Giordano, Antonio

AU - Martino, Bruno

AU - Melillo, Lorella

AU - Nadali, Gianpaolo

AU - Perriello, Vincenzo

AU - Picardi, Marco

AU - Quinto, Angela Maria

AU - Salutari, Prassede

AU - Spolzino, Angelica

AU - Vacca, Adriana

AU - Vetro, Calogero

AU - Zancanella, Michelle

AU - Nosari, Annamaria

AU - Aversa, Franco

AU - Pagano, Livio

PY - 2018

Y1 - 2018

N2 - The purpose of the present study is to estimate the current incidence of febrile events (FEs) and infectious episodes in acute lymphoblastic leukemia (ALL) and evaluate the outcome. We analyzed data on all FEs in a cohort of patients affected by ALL admitted to 20 Italian hematologic centers during 21 months of observation from April 1, 2012 to December 31, 2013. Data about treatment phase, steroids, neutropenia, type and site of infection, and outcome of infection were collected. The population comprehended 271 ALL adult patients. Median age was 46 years old (range 19–75), M/F 1.1:1. We collected 179 FEs occurring during 395 different phases of treatment in 127 patients (45.3% incidence): remission induction treatment 53.1%, consolidation/maintenance 35.7%, treatment for a first or second relapse 44.3%, and refractory disease 85.7%. The incidence of FUO (fever of unknown origin) was 55/395 (13.9%). In the remaining cases, bacteria caused 92 FEs (23.2%), fungi 17 (4.3%), viruses 5 (1%). Mixed infections occurred in 10 cases mainly fungal+bacterial (9/10 cases). Neutropenia was mostly present at onset of FE (89.9% of FEs). Mortality rate was 11.7% (21/179) while 16 deaths occurred with evidence of infection (8.9%). Age > 60 years, neutropenia, poor performance status, steroids, refractory disease, and mixed infections significantly correlated with infection-related mortality. A statistically significant association with mortality was observed also for pulmonary localization and bacteremia. Our study describes the real-life epidemiological scenario of infections in ALL and identifies a subset of patients who are at higher risk for infection-related mortality.

AB - The purpose of the present study is to estimate the current incidence of febrile events (FEs) and infectious episodes in acute lymphoblastic leukemia (ALL) and evaluate the outcome. We analyzed data on all FEs in a cohort of patients affected by ALL admitted to 20 Italian hematologic centers during 21 months of observation from April 1, 2012 to December 31, 2013. Data about treatment phase, steroids, neutropenia, type and site of infection, and outcome of infection were collected. The population comprehended 271 ALL adult patients. Median age was 46 years old (range 19–75), M/F 1.1:1. We collected 179 FEs occurring during 395 different phases of treatment in 127 patients (45.3% incidence): remission induction treatment 53.1%, consolidation/maintenance 35.7%, treatment for a first or second relapse 44.3%, and refractory disease 85.7%. The incidence of FUO (fever of unknown origin) was 55/395 (13.9%). In the remaining cases, bacteria caused 92 FEs (23.2%), fungi 17 (4.3%), viruses 5 (1%). Mixed infections occurred in 10 cases mainly fungal+bacterial (9/10 cases). Neutropenia was mostly present at onset of FE (89.9% of FEs). Mortality rate was 11.7% (21/179) while 16 deaths occurred with evidence of infection (8.9%). Age > 60 years, neutropenia, poor performance status, steroids, refractory disease, and mixed infections significantly correlated with infection-related mortality. A statistically significant association with mortality was observed also for pulmonary localization and bacteremia. Our study describes the real-life epidemiological scenario of infections in ALL and identifies a subset of patients who are at higher risk for infection-related mortality.

KW - Acute lymphoblastic leukemia

KW - Epidemiology

KW - Febrile events

KW - Infections

UR - http://www.scopus.com/inward/record.url?scp=85041597453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041597453&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3252-6

DO - 10.1007/s00277-018-3252-6

M3 - Article

AN - SCOPUS:85041597453

VL - 97

SP - 791

EP - 798

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -